BlackRock’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $303K | Sell |
62,226
-4
| -0% | -$22 | ﹤0.01% | 4648 |
|
|
2025
Q4 | $416K | Buy |
62,230
+93
| +0.1% | +$552 | ﹤0.01% | 4527 |
|
|
2025
Q3 | $272K | Sell |
62,137
-49,321
| -44% | -$234K | ﹤0.01% | 4617 |
|
|
2025
Q2 | $495K | Sell |
111,458
-170,588
| -60% | -$713K | ﹤0.01% | 4440 |
|
|
2025
Q1 | $1.6M | Sell |
282,046
-16,095
| -5% | -$206K | ﹤0.01% | 4061 |
|
|
2024
Q4 | $6.29M | Buy |
298,141
+6,523
| +2% | +$150K | ﹤0.01% | 3633 |
|
|
2024
Q3 | $7.84M | Buy |
291,618
+7,253
| +3% | +$214K | ﹤0.01% | 3527 |
|
|
2024
Q2 | $8.1M | Buy |
284,365
+999
| +0.4% | +$35K | ﹤0.01% | 3495 |
|
|
2024
Q1 | $12M | Sell |
283,366
-8,015
| -3% | -$360K | ﹤0.01% | 3256 |
|
|
2023
Q4 | $15.6M | Buy |
291,381
+17,113
| +6% | +$773K | ﹤0.01% | 3147 |
|
|
2023
Q3 | $11.8M | Buy |
274,268
+11,893
| +5% | +$549K | ﹤0.01% | 3239 |
|
|
2023
Q2 | $14.4M | Buy |
262,375
+171,900
| +190% | +$9.43M | ﹤0.01% | 3225 |
|
|
2023
Q1 | $3.8M | Buy |
90,475
+67
| +0.1% | +$1.99K | ﹤0.01% | 3756 |
|
|
2022
Q4 | $2.5M | Sell |
90,408
-28,902
| -24% | -$712K | ﹤0.01% | 4043 |
|
|
2022
Q3 | $3.05M | Sell |
119,310
-1,602
| -1% | -$53K | ﹤0.01% | 3975 |
|
|
2022
Q2 | $4.35M | Sell |
120,912
-184,888
| -60% | -$8.34M | ﹤0.01% | 3885 |
|
|
2022
Q1 | $19M | Sell |
305,800
-519
| -0.2% | -$30.7K | ﹤0.01% | 3199 |
|
|
2021
Q4 | $21.6M | Buy |
306,319
+32,572
| +12% | +$2.32M | ﹤0.01% | 3229 |
|
|
2021
Q3 | $19.1M | Buy |
273,747
+605
| +0.2% | +$48.1K | ﹤0.01% | 3307 |
|
|
2021
Q2 | $22.8M | Sell |
273,142
-23,613
| -8% | -$1.67M | ﹤0.01% | 3221 |
|
|
2021
Q1 | $16.2M | Buy |
296,755
+1,364
| +0.5% | +$66.4K | ﹤0.01% | 3298 |
|
|
2020
Q4 | $12.7M | Buy |
295,391
+15,155
| +5% | +$566K | ﹤0.01% | 3249 |
|
|
2020
Q3 | $8.43M | Buy |
280,236
+4,964
| +2% | +$167K | ﹤0.01% | 3320 |
|
|
2020
Q2 | $8.54M | Buy |
275,272
+164,680
| +149% | +$4.44M | ﹤0.01% | 3271 |
|
|
2020
Q1 | $2.44M | Sell |
110,592
-276
| -0.2% | -$7.48K | ﹤0.01% | 3595 |
|
|
2019
Q4 | $3.38M | Sell |
110,868
-5,489
| -5% | -$158K | ﹤0.01% | 3621 |
|
|
2019
Q3 | $3.58M | Sell |
116,357
-28,511
| -20% | -$709K | ﹤0.01% | 3582 |
|
|
2019
Q2 | $2.9M | Sell |
144,868
-152,952
| -51% | -$4.48M | ﹤0.01% | 3664 |
|
|
2019
Q1 | $12.8M | Sell |
297,820
-8,898
| -3% | -$323K | ﹤0.01% | 2988 |
|
|
2018
Q4 | $9.75M | Buy |
306,718
+7,343
| +2% | +$289K | ﹤0.01% | 3098 |
|
|
2018
Q3 | $15.7M | Buy |
299,375
+5,948
| +2% | +$334K | ﹤0.01% | 3000 |
|
|
2018
Q2 | $15.7M | Buy |
293,427
+150,467
| +105% | +$7.71M | ﹤0.01% | 2995 |
|
|
2018
Q1 | $7.15M | Sell |
142,960
-5,045
| -3% | -$226K | ﹤0.01% | 3277 |
|
|
2017
Q4 | $4.88M | Sell |
148,005
-6,411
| -4% | -$216K | ﹤0.01% | 3449 |
|
|
2017
Q3 | $5.79M | Sell |
154,416
-813
| -0.5% | -$24K | ﹤0.01% | 3426 |
|
|
2017
Q2 | $3.96M | Sell |
155,229
-3,993
| -3% | -$98.8K | ﹤0.01% | 3532 |
|
|
2017
Q1 | $4.14M | Buy |
+159,222
| New | +$4.59M | ﹤0.01% | 3444 |
|
|
2016
Q2 | – | Sell |
-48
| Closed | -$1K | – | 3758 |
|
|
2016
Q1 | $1K | Buy |
+48
| New | +$1.36K | ﹤0.01% | 3527 |
|
Other funds holding HBIO
WCM
VCM
CCM
MIM
NCNMGF
BlackRock's HBIO Position: Q1 2026 in Review
BlackRock reduced its Harvard Bioscience (HBIO) stake by 0.01% in Q1 2026, selling an estimated $22 and leaving 62,226 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #4648.
BlackRock first reported a position in HBIO in Q1 2016 and has held it in 38 quarters since. The position peaked at $22.8M in Q2 2021. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.
- BlackRock held 62,226 shares of Harvard Bioscience worth $303K as of Q1 2026.
- BlackRock sold 4 Harvard Bioscience shares in Q1 2026, an estimated $22.
- Harvard Bioscience made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4648 holding.
- BlackRock first reported a position in Harvard Bioscience in Q1 2016 and has held it in 38 quarters since.
- BlackRock's Harvard Bioscience position peaked at $22.8M in Q2 2021.
- 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.